STOIC BIO, INC
Summary
Gene Therapy, Precision Medicine, Cell Therapy, Cell Culture, Research and Development, Manufacturing, Scalable Manufacturing Solutions, Sustainability, Environmental sustainability, Supply Chain, Cell Media, Growth Media, Medical Countermeasures, Infrastructure, Vaccine Infrastructure, National Health Resilience, Laboratory Equipment, GMP Manufacturing, Manufacturing Automation, Lean Manufacturing, Supply Chain Cost Reduction, Production Cost Reduction, Global Health Defense, Vaccine Manufacturing
Profile
Address
Classification
Description
With proficiency in complex product and process development in regulated industries, digital platforms and user experience, and performance cell culture media development, Stoic Bio offers the only point-of-use, on-demand cell culture media and buffer manufacturing system that provides a fully-automated, user-friendly, pod-based user experience at the 500mL to 10,000 Liter scale. The Krakatoa[R] system provides the freshest, performance optimized media formulations that are delivered at 60% cost with up to 3x extended shelf-life compared to conventional liquid media. Krakatoa streamlines the supply chain for vaccine and therapy production, establishing a significantly stronger defense against global health threats and a 65% reduction in overall greenhouse gas emissions. Stoic Bio's R&D lab scale system was commercially released in 2023 and provides the Proof of Concept for the larger scale production system. The K100 production-scale prototype system was released in 2023.
